Global Non-Small Cell Lung Cancer Market 2020 By Type [Squamous cell (epidermoid) carcinoma, Adenocarcinoma, Large cell (undifferentiated) carcinoma and others], By Therapy [Chemotherapy, Radiotherapy,Laser therapy,Photodynamic therapy (PDT) and Others], By Distribution Channel[Hospital pharmacies,Online pharmacies and Others]: Global Forecast to 2026 and COVID-19 Impact Outlook

Pages: 209 | Published Date: October 2020 | Report ID: 4935 Sectors , ,

From $2,990.00

  • Single User
  • Multi User
  • Corporate User
Clear

COVID-19

As Covid-19 outbreak has major economical impact on global business. Get the detailed insight about COVID-19 impression on your business...

REPORT DESCRIPTION

Global Non-Small Cell Lung Cancer Market is valued at USD 7.53 Billion (€ 6.47 Bn) in 2019 and expected to reach USD 12.89 Billion (€ 11.08 Bn) by 2026 with the CAGR of 7.9 % over the forecast period.

Scope of the report

This report analyses the global market for Non-Small Cell Lung Cancer. The report will enable the user to understand and gain insights into the current and forecast market situation. The market is comprehensively analyzed by geography to give complete information on the global scenario. The qualitative and quantitative data provided in this study can help user understand which market segments, regions are expected to grow at higher rates, factors affecting the market and key opportunity areas. The report also includes competitive landscape of key players in the industry along with emerging trends in the market.

Key Players

Agennix AG, AstraZeneca,Eli Lily,GlaxoSmithKline,Merck & Co.,Novartis AG,Pfizer,Roche and others
Above mentioned companies were scrutinized to assess competitive landscape of global Non-Small Cell Lung Cancer market. Report provides company profiles of each player. Each profile include company product portfolio,business overview, company governance, company financials, business strategies, manufacturing locations and production facilities, company sale, recent developments and strategic collaborations & partnerships, new product launch, company segments, application diversification and company strength and weakness analysis.

Review period: (2016-2026)
Historic Period: 2016 to 2019
Forecast Period: 2020 to 2026
Base Year: 2019
Unit: USD Billion

This Non-Small Cell Lung Cancer market report provides insights on new trade regulations, import export analysis, industry value chain analysis, market size, consumption, production analysis, capacity analysis, regional and segment market share, product launches, product pipeline analysis, impact of Covid-19 on supply chain, key regions, untapped markets, patent analysis, product approvals, continuous innovations and developments in the market.

Regions

• North America: U.S., Canada and Rest of North America
• Europe: UK, France, Germany, Italy, Spain and Rest of Europe
• Asia Pacific: China, Japan, India, Australia, Southeast Asia and Rest of Asia Pacific
• Latin America: Brazil, Mexico, Argentina and Rest of Latin America
• Middle East and Africa: Gulf Countries, Israel, Africa and Rest of Middle East and Africa

Market Segmentation
• Type
o Squamous cell (epidermoid) carcinoma
o Adenocarcinoma
o Large cell (undifferentiated) carcinoma
o Other
• Therapy
o Chemotherapy
o Radiotherapy
o Laser therapy
o Photodynamic therapy (PDT)
o Others
• Distribution Channel
o Hospital pharmacies
o Online pharmacies
o Others


Report Coverage

• An overview of the global Non-Small Cell Lung Cancer market
• In depth analysis of market dynamics and major factors such as drivers, restraints, opportunities and trends influencing the global market
• Global Non-Small Cell Lung Cancer market revenue data historic and forecast analysis (2016 to 2026)
• Characterization and quantification of the market segments for Non-Small Cell Lung Cancer market
• Market share analysis of key market participants and their competitive landscape

Important Questions Answered by Global Non-Small Cell Lung Cancer Market Report

• What is the impact of COVID 19 epidemic on the global Non-Small Cell Lung Cancer market?
• Which is mostly affected region, country?
• Which is the current largest and fastest-growing region?
• What is the market size and growth rate of the global Non-Small Cell Lung Cancer market?
• What are current factors affecting the growth of market?
• What are Key trends and opportunity areas?
• Within Non-Small Cell Lung Cancer market, which segments are fastest growing & emerging strongly? What are the drivers and restraints for each segment? What are vendor competencies by segment?
• What are the major strategies adopted by leading market companies?
• What are company challenges and essential success factors by market segment?
• How company offerings and supply chain capabilities are shifting to meet emerging market needs?

TABLE OF CONTENT

1. Introduction
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
1.4. List of Abbreviations
2. Executive Summary
3. Market Overview
3.1. Market Definition
3.2. Market Scope
3.3. Market Drivers
3.4. Market Restraints
3.5. Market Opportunities and Trends
3.6. Porter’s five force analysis
3.7. SWOT Analysis
3.8. PEST Analysis
3.9. Patent Analysis
3.10. Impact of COVID 19 on Global Non-Small Cell Lung Cancer Market
4. Non-Small Cell Lung Cancer Market, By Type, Market Size and Forecast 2016 -2026 (USD Billion)
4.1. Global Non-Small Cell Lung Cancer Market By Type, 2016 -2026 (USD Billion)
4.1.1. Global Non-Small Cell Lung Cancer Market By Squamous cell (epidermoid) carcinoma
4.1.2. Global Non-Small Cell Lung Cancer Market By Adenocarcinoma
4.1.3. Global Non-Small Cell Lung Cancer Market By Large cell (undifferentiated) carcinoma
4.1.4. Global Non-Small Cell Lung Cancer Market By Other
4.2. Global Non-Small Cell Lung Cancer Market By Type Share, 2016 -2026 (%)
5. Non-Small Cell Lung Cancer Market, By Distribution Channel, Market Size and Forecast 2016 -2026 (USD Billion)
5.1. Global Non-Small Cell Lung Cancer Market By Distribution Channel, 2016 -2026 (USD Billion)
5.1.1. Global Non-Small Cell Lung Cancer Market By Hospital pharmacies
5.1.2. Global Non-Small Cell Lung Cancer Market By Online pharmacies
5.1.3. Global Non-Small Cell Lung Cancer Market By Others
5.2. Global Non-Small Cell Lung Cancer Market By Distribution Channel Share, 2016 -2026 (%)
6. Non-Small Cell Lung Cancer Market, By Therapy, Market Size and Forecast 2016 -2026 (USD Billion)
6.1. Global Non-Small Cell Lung Cancer Market By Therapy, 2016 -2026 (USD Billion)
6.1.1. Global Non-Small Cell Lung Cancer Market By Chemotherapy
6.1.2. Global Non-Small Cell Lung Cancer Market By Radiotherapy
6.1.3. Global Non-Small Cell Lung Cancer Market By Laser therapy
6.1.4. Global Non-Small Cell Lung Cancer Market By Photodynamic therapy (PDT)
6.1.5. Global Non-Small Cell Lung Cancer Market By Others
6.2. Global Non-Small Cell Lung Cancer Market By Therapy Share, 2016 -2026 (%)
7. Non-Small Cell Lung Cancer Market, By Region Market Size and Forecast 2016 -2026
7.1. NORTH AMERICA
7.1.1. Key Findings
7.1.2. Impact of COVID 19
7.1.3. Key market trends, growth factors and opportunities
7.1.4. North America Non-Small Cell Lung Cancer Market by Country 2016 -2026 (USD Billion)
7.1.5. North America Non-Small Cell Lung Cancer Market By Type 2016 -2026 (USD Billion)
7.1.6. North America Non-Small Cell Lung Cancer Market By Therapy 2016 -2026 (USD Billion)
7.1.7. North America Non-Small Cell Lung Cancer Market By Distribution Channel 2016 -2026 (USD Billion)
7.2. EUROPE
7.2.1. Key Findings
7.2.2. Impact of COVID 19
7.2.3. Key market trends, growth factors and opportunities
7.2.4. Europe Non-Small Cell Lung Cancer Market by Country 2016 -2026 (USD Billion)
7.2.5. Europe Non-Small Cell Lung Cancer Market By Type 2016 -2026 (USD Billion)
7.2.6. Europe Non-Small Cell Lung Cancer Market By Therapy 2016 -2026 (USD Billion)
7.2.7. Europe Non-Small Cell Lung Cancer Market By Distribution Channel 2016 -2026 (USD Billion)
7.3. ASIA PACIFIC
7.3.1. Key Findings
7.3.2. Impact of COVID 19
7.3.3. Key market trends, growth factors and opportunities
7.3.4. Asia Pacific Non-Small Cell Lung Cancer Market by Country 2016 -2026 (USD Billion)
7.3.5. Asia Pacific Non-Small Cell Lung Cancer Market By Type 2016 -2026 (USD Billion)
7.3.6. Asia Pacific Non-Small Cell Lung Cancer Market By Therapy 2016 -2026 (USD Billion)
7.3.7. Asia Pacific Non-Small Cell Lung Cancer Market By Distribution Channel 2016 -2026 (USD Billion)
7.4. LATIN AMERICA
7.4.1. Key Findings
7.4.2. Impact of COVID 19
7.4.3. Key market trends, growth factors and opportunities
7.4.4. Latin America Non-Small Cell Lung Cancer Market by Country 2016 -2026 (USD Billion)
7.4.5. Latin America Non-Small Cell Lung Cancer Market By Type 2016 -2026 (USD Billion)
7.4.6. Latin America Non-Small Cell Lung Cancer Market By Therapy 2016 -2026 (USD Billion)
7.4.7. Latin America Non-Small Cell Lung Cancer Market By Distribution Channel 2016 -2026 (USD Billion)
7.5. MIDDLE EAST AND AFRICA
7.5.1. Key Findings
7.5.2. Impact of COVID 19
7.5.3. Key market trends, growth factors and opportunities
7.5.4. Middle East and Africa Non-Small Cell Lung Cancer Market by Country 2016 -2026 (USD Billion)
7.5.5. Middle East and Africa Non-Small Cell Lung Cancer Market By Type 2016 -2026 (USD Billion)
7.5.6. Middle East and Africa Non-Small Cell Lung Cancer Market By Therapy 2016 -2026 (USD Billion)
7.5.7. Middle East and Africa Non-Small Cell Lung Cancer Market By Distribution Channel 2016 -2026 (USD Billion)
8. Competitive Landscape Analysis
8.1. Global Non-Small Cell Lung Cancer Market Company Revenue, (USD Billion), 2016-2019
8.2. Global Non-Small Cell Lung Cancer Market Company Share, (%), 2016-2019
9. Company Profiles
9.1. Agennix AG, AstraZeneca
9.2. Eli Lily
9.3. GlaxoSmithKline
9.4. Merck & Co.
9.5. Novartis AG
9.6. Pfizer
9.7. Roche
9.8. Others

10. Appendix
11. List of Tables
12. List of Figures

Name
Email
Phone
Enquiry

Request Free Sample Report